SCHEDULE: Balderton Capital Reduces Sophia Genetics Stake Below 5%
Beneficial Ownership Report
Balderton Capital VI, S.L.P. has filed an Amendment No. 3 to its Schedule 13G, reporting beneficial ownership of 4.9% of Sophia Genetics SA's Ordinary Shares.
Summary
- Balderton Capital VI, S.L.P. (the "Reporting Person") now beneficially owns 3,301,240 Ordinary Shares of Sophia Genetics SA.
- This represents 4.9% of the Issuer's Ordinary Shares outstanding.
- The percentage is based on 67,579,560 Ordinary Shares outstanding as of June 30, 2025, as reported in the Issuer's prospectus on Form 424(b)(5) filed on August 15, 2025.
- The Reporting Person, through its managing general partner BCVI Sarl, holds shared voting and dispositive power over all these shares.
- This filing is Amendment No. 3 to the original Schedule 13G filed on February 10, 2022, with previous amendments on February 13, 2024, and February 20, 2024.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a moderately negative signal, as a significant institutional investor reducing its stake below 5% could imply a diminished long-term outlook or a strategic exit.
Negatives
- Balderton Capital VI, S.L.P. has reduced its beneficial ownership in Sophia Genetics SA to below the 5% threshold, indicating a potential divestment or reduced conviction.
Risks
- The reduction of a significant investor's stake below 5% could signal a lack of confidence or a strategic portfolio reallocation by Balderton Capital VI, S.L.P.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that a reduction in a significant institutional investor's stake, particularly below a key reporting threshold like 5%, can sometimes be interpreted by the market as a signal regarding the investor's long-term view on the company or a strategic portfolio rebalancing. This is a common occurrence in the venture capital and private equity space as firms mature and seek liquidity.
Stakeholder Impact
- Shareholders: May interpret the reduction in Balderton Capital's stake as a negative signal, potentially impacting share price.
- Management: Could face questions regarding the reasons for the investor's reduced position.
Key Dates
| Date | Description |
|---|---|
| 2022-02-10 | Original Schedule 13G filed with the SEC by the Reporting Persons. |
| 2024-02-13 | Amendment No. 1 to Schedule 13G filed with the SEC. |
| 2024-02-20 | Amendment No. 2 to Schedule 13G filed with the SEC. |
| 2025-06-30 | Date as of which 67,579,560 Ordinary Shares were outstanding, used for percentage calculation. |
| 2025-08-15 | Issuer's prospectus on Form 424(b)(5) filed with the United States Securities and Exchange Commission. |
| 2025-12-31 | Date of event which required the filing of this statement (beneficial ownership change). |
| 2026-02-11 | Date Amendment No. 3 to Schedule 13G was signed by Petr Klimo, Manager of Balderton Capital General Partner VI, S.a.r.l. |
Recommendation
holdThe reduction of Balderton Capital's stake below 5% is a notable event, suggesting a potential shift in investor confidence or portfolio strategy. While not an immediate 'sell' signal, it warrants a 'hold' recommendation for investors to re-evaluate Sophia Genetics SA's fundamentals and future prospects in light of this institutional divestment.
Keywords
Sophia Genetics SA, Balderton Capital, Schedule 13G, Beneficial Ownership, Equity Stake, Institutional Investor, H82027105, Ordinary Shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.